Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase Ⅲ Clinical Study

NCT07306663 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

242

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer

Interventions

BIOLOGICAL: Sintilimab
DRUG: 3-Weekly Paclitaxel plus Carboplatin (TC) Chemotherapy
DRUG: Weekly TC Chemotherapy
DRUG: Four-Weekly TC Consolidation Chemotherapy
RADIATION: Definitive Radiotherapy

Sponsor

Jiangsu Cancer Institute & Hospital

Collaborators

[object Object]